1
|
Kopanska K, Pastor M. P04-10 Application of Dempster-Shafer theory to estimate uncertainty in hazard assessment obtained by combining computational and experimental results. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Kopanska K, Gómez-Tamayo J, Llopis-Lorente J, Trenor-Gomis B, Sáiz J, Pastor M. Estimation of uncertainty in multi-level in silico models predicting biomarkers of drug-induced proarrhythmic risk. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00399-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Badal B, Ballesteros A, Crespo M, Morell-Garcia D, Bauçà JM, Pastor M, Ruiz de Gopegui R, Martín I. Quality control of ultrasonography markers for Down's syndrome screening: a retrospective study by the laboratory. Diagnosis (Berl) 2021; 0:dx-2021-0007. [PMID: 34090321 DOI: 10.1515/dx-2021-0007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 04/27/2021] [Indexed: 11/15/2022]
Abstract
OBJECTIVES Quality control of ultrasonography markers is necessary to ensure greater efficacy of prenatal aneuploidy screening. The aim of this study was to assess the quality of the crown-rump length (CRL) and nuchal translucence (NT) measurement accuracy by the laboratory according to quality indicators. METHODS Retrospective observational study on 4,908 single-foetus pregnant women who underwent prenatal aneuploidy screening in the first trimester of pregnancy. Euploid foetuses with CRL between 45 and 84 mm were included, while those with NT≥3.5 mm were excluded. CRL measurement was considered to be accurate if the median multiples of the median (MoM) for pregnancy-associated plasma protein A (PAPP-A) was between 0.90 and 1.10. Fifteen sonographers participated in the study, six of whom comprised the control group. Systematic error for a sonographer was considered when CRL measurement was greater than ±2 mm with respect to the control group. Quality for NT was assured by means of the WHIRI method and each sonographer cumulative sum control chart (CUSUM). RESULTS For CRL accuracy, five sonographers underestimated the measurements, while another four overestimated them, with no statistical differences. For smaller sized foetuses, all sonographers met the established specifications. Regarding NT control, three sonographers did not meet the quality criteria for the median MoM. All sonographers met the specifications for the logarithmic standard deviation of the NT MoM levels. Thirteen sonographers met the CUSUM specifications. CONCLUSIONS Evaluation of a quality control of ultrasonography parameters by laboratory professionals is necessary to avoid under- or overestimation tendencies for CRL and NT measurements. CUSUM is a useful tool for the immediate correction of errors in NT measurements.
Collapse
Affiliation(s)
- Blanca Badal
- Laboratory Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
| | - Antonieta Ballesteros
- Laboratory Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
| | - Miriam Crespo
- Laboratory Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
| | - Daniel Morell-Garcia
- Laboratory Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
- Institut de Recerca Sanitària de les Illes Balears (IdISBa), Palma de Mallorca, Spain
| | - Josep Miquel Bauçà
- Laboratory Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
- Institut de Recerca Sanitària de les Illes Balears (IdISBa), Palma de Mallorca, Spain
| | - Maria Pastor
- Laboratory Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
| | - Rosa Ruiz de Gopegui
- Gynecology and Obstetrics Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
| | - Inmaculada Martín
- Laboratory Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
| |
Collapse
|
4
|
Correa J, Pastor M, Céspedes E, Magliano J, Bazzano C. Tissue-Sparing Outcome of Mohs Micrographic Surgery in Squamous Cell Carcinomas. Actas Dermo-Sifiliográficas (English Edition) 2020. [DOI: 10.1016/j.adengl.2020.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Carreras G, Lachi A, Cortini B, Gallus S, López M, Nicolás Á, Lugo A, Pastor M, Soriano J, Fernandez E, Gorini G. Burden of disease from exposure to secondhand smoke in children in Europe. Tob Prev Cessat 2020. [DOI: 10.18332/tpc/128300] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Correa J, Pastor M, Céspedes E, Magliano J, Bazzano C. Tissue-Sparing Outcome of Mohs Micrographic Surgery in Squamous Cell Carcinomas. Actas Dermosifiliogr (Engl Ed) 2020; 111:847-851. [PMID: 32717186 DOI: 10.1016/j.ad.2020.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 07/04/2020] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND Micrographic Mohs Surgery (MMS) offers the highest cure rates and healthy skin tissue sparing effect compared with standard excision. OBJECTIVE To quantify the tissue-sparing properties of MMS in squamous cell carcinoma (SCC) in comparison with standard excision (SE). METHODS A bidirectional, descriptive study, including 94 cases of SCC, was performed, on patients with histologic diagnosis of SCC (in situ, well differentiated, moderately differentiated, and undifferentiated), that where operated with MMS between 2013 and 2018 at Hospital de Clínicas Dr. Manuel Quintela in Montevideo, Uruguay. Tumor size and defect area after MMS were measured in 2 perpendicular directions. The suspected defect area was calculated with standard excision using a 4-mm margin for low risk lesions and a 10-mm margin for high risk lesions. The primary outcome of this study was the size of the defect area post MMS compared with the calculated defect area with standard excision. RESULTS The median tumor size was 1,41mm2, and the median defect size after MMS was 4,12mm2. The median defect size calculated for standard surgical excision was 8,36mm2. LIMITATIONS We do not use all National Comprehensive Cancer Network (NCCN) criteria. We define low and high risk lesions just taking into account anatomical location, size, histopathology and whether it was a primary or recurrent tumor. CONCLUSION Our results show that MMS has a tissue-sparing effect of at least 52% compared to SE.
Collapse
Affiliation(s)
- J Correa
- Unidad de Cirugía Dermatológica, Hospital Dr. Manuel Quintela, Universidad de la República, Montevideo, Uruguay.
| | - M Pastor
- Unidad de Cirugía Dermatológica, Hospital Dr. Manuel Quintela, Universidad de la República, Montevideo, Uruguay
| | - E Céspedes
- Unidad de Cirugía Dermatológica, Hospital Dr. Manuel Quintela, Universidad de la República, Montevideo, Uruguay
| | - J Magliano
- Unidad de Cirugía Dermatológica, Hospital Dr. Manuel Quintela, Universidad de la República, Montevideo, Uruguay
| | - C Bazzano
- Unidad de Cirugía Dermatológica, Hospital Dr. Manuel Quintela, Universidad de la República, Montevideo, Uruguay
| |
Collapse
|
7
|
Vairo C, Basas J, Pastor M, Palau M, Gomis X, Almirante B, Gainza E, Hernandez RM, Igartua M, Gavaldà J, Gainza G. In vitro and in vivo antimicrobial activity of sodium colistimethate and amikacin-loaded nanostructured lipid carriers (NLC). Nanomedicine 2020; 29:102259. [PMID: 32619707 DOI: 10.1016/j.nano.2020.102259] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 04/03/2020] [Accepted: 06/21/2020] [Indexed: 01/18/2023]
Abstract
Sodium colistimethate (SCM) and amikacin (AMK) are among the few antibiotics effective against resistant P. aeruginosa, K. pneumoniae and A. baumannii; however, their toxicity severely limits their use. Enclosing antibiotics into nanostructured lipid carriers (NLC) might decrease drug toxicity and improve antibiotic disposition. In this work, SCM or AMK was loaded into different NLC formulations, through high pressure homogenization, and their in vitro and in vivo effectiveness was analyzed. The encapsulation process did not reduce drug effectiveness since in vitro SCM-NLC and AMK-NLC drug activity was equal to that of the free drugs. As cryoprotectant, trehalose showed better properties than dextran. Instead, positive chitosan coating was discarded due to its limited cost-efficiency. Finally, the in vivo study in acute pneumonia model revealed that intraperitoneal administration was superior to the intramuscular route and confirmed that (-) SCM-NLC with trehalose, was the most suitable formulation against an extensively drug-resistant A. baumannii strain.
Collapse
Affiliation(s)
- C Vairo
- BioKeralty Research Institute AIE, Miñano, Spain; NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Vitoria-Gasteiz, Spain
| | - J Basas
- Antimicrobial Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, Barcelona
| | - M Pastor
- BioKeralty Research Institute AIE, Miñano, Spain
| | - M Palau
- Antimicrobial Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, Barcelona
| | - X Gomis
- Antimicrobial Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, Barcelona
| | - B Almirante
- Antimicrobial Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, Barcelona
| | - E Gainza
- BioKeralty Research Institute AIE, Miñano, Spain
| | - R M Hernandez
- NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - M Igartua
- NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country (UPV/EHU), School of Pharmacy, Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain
| | - J Gavaldà
- Antimicrobial Resistance Laboratory, Vall d'Hebron Research Institute (VHIR), Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Passeig de la Vall d'Hebron, Barcelona.
| | - G Gainza
- BioKeralty Research Institute AIE, Miñano, Spain.
| |
Collapse
|
8
|
Picard-Deland C, Pastor M, Solomonova E, Paquette T, Nielsen T. 0088 Gravity Dreams Following a Virtual Reality Flight Simulation. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Flying is a prevalent but infrequent experience in dreams. Despite a broad interest in such unique dream experiences, there is still no experimental procedure for reliably inducing them. Our study aimed 1) to induce flying dreams in the laboratory using virtual reality (VR), 2) to examine phenomenological correlates of flying dreams, such as lucidity and emotions and 3) to investigate the dynamics of dreamed gravity imagery in relation to participant state and trait factors.
Methods
A total of 137 healthy participants (24.01±4.03 y.o.; 85 F; 52 M) took part in a custom-built immersive VR task in which they learn how to ‘fly’ as precisely and quickly as possible, engaging vestibular, motor and visuo-spatial systems. Dreams were collected a) from home dream journals for 5 days before and 10 days after the laboratory VR task and b) after a 90-min morning nap in laboratory. Dream reports were scored by 2 independent judges for flying and other gravity-related imagery. Linear mixed models statistics were used to compare dreams from this cohort with a separate control cohort (N=52) that followed a similar protocol in the same lab but did not undertake a virtual flying task.
Results
The VR task successfully increased the likelihood of experiencing flying in dreams from both the laboratory nap (7.1%) and the following night (10.6%) compared to baseline (1.3%) and the control cohort on those days (Lab: 2.4%; following night: 0%). In contrast, the occurrence of other gravity imagery showed no differences. Flying dreams were altered qualitatively, exhibiting higher levels of lucid-control and emotional intensity after VR exposure. Moreover, various factors such as sex, prior dream experiences and sensory immersion in VR differentially modulated flying dream induction.
Conclusion
Our findings provide both quantitative and qualitative insights into flying dreams that may facilitate understanding of these typical dream experiences and future developments in dream flight-induction technologies.
Support
Natural Sciences and Engineering Research Council of Canada
Collapse
Affiliation(s)
- C Picard-Deland
- Université de Montréal, Neuroscience Department, Montreal, QC, CANADA
| | - M Pastor
- Dream & Nightmare Laboratory; Center for Advanced Research in Sleep Medicine, Montreal, QC, CANADA
| | - E Solomonova
- McGill University; Department of Psychiatry, Montreal, QC, CANADA
| | - T Paquette
- Dream & Nightmare Laboratory; Center for Advanced Research in Sleep Medicine, Montreal, QC, CANADA
| | - T Nielsen
- Dream & Nightmare Laboratory; Center for Advanced Research in Sleep Medicine, Montreal, QC, CANADA
| |
Collapse
|
9
|
Bouza E, Alvar A, Almagro P, Alonso T, Ancochea J, Barbé F, Corbella J, Gracia D, Mascarós E, Melis J, Miravitlles M, Pastor M, Pérez P, Rudilla D, Torres A, Soriano JB, Vallano A, Vargas F, Palomo E. Chronic obstructive pulmonary disease (COPD) in Spain and the different aspects of its social impact: a multidisciplinary opinion document. Rev Esp Quimioter 2020; 33:49-67. [PMID: 31933347 PMCID: PMC6987629 DOI: 10.37201/req/2064.2019] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 10/24/2019] [Accepted: 12/02/2019] [Indexed: 12/21/2022]
Abstract
Chronic obstructive pulmonary disease (COPD) is one of the most prevalent diseases in the World, and one of the most important causes of mortality and morbidity. In adults 40 years and older, it affects more than 10% of the population and has enormous personal, family and social burden. Tobacco smoking is its main cause, but not the only one, and there is probably a genetic predisposition that increases the risk in some patients. The paradigm of this disease is changing in Spain, with an increase of women that has occurred in recent years. Many of the physio pathological mechanisms of this condition are well known, but the psychological alterations to which it leads, the impact of COPD on relatives and caregivers, the limitation of daily life observed in these patients, and the economic and societal burden that they represent for the health system, are not so well-known. A major problem is the high under-diagnosis, mainly due to difficulties for obtaining, in a systematic way, spirometries in hospitals and health-care centers. For this reason, the Fundación de Ciencias de la Salud and the Spanish National Network Center for Research in Respiratory Diseases (CIBERES) have brought together experts in COPD, patients and their organizations, clinical psychologists, experts in health economics, nurses and journalists to obtain their opinion about COPD in Spain. They also discussed the scientific bibliometrics on COPD that is being carried out from the CIBERES and speculated on the future of this condition. The format of the meeting consisted in the discussion of a series of questions that were addressed by different speakers and discussed until a consensus conclusion was reached.
Collapse
Affiliation(s)
- E Bouza
- Emilio Bouza MD, PhD, Instituto de Investigación Sanitaria Gregorio Marañón, C/ Dr. Esquerdo, 46 - 28007 Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - E Palomo
- Esteban Palomo, PhD, Director. Fundación de Ciencias de la Salud. C/ Severo Ochoa, 2, - 28760 Tres Cantos. Madrid, Spain. Phone +34 91 3530150
| |
Collapse
|
10
|
Vairo C, Collantes M, Quincoces G, Villullas S, Peñuelas I, Pastor M, Gil A, Gainza E, Hernandez R, Igartua M, Gainza G. Preclinical safety of topically administered nanostructured lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies. Int J Pharm 2019; 569:118484. [DOI: 10.1016/j.ijpharm.2019.118484] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Revised: 06/26/2019] [Accepted: 06/27/2019] [Indexed: 12/23/2022]
|
11
|
Graepel R, Ter Braak B, Escher S, Fisher C, Gardner I, Kamp H, Kroese D, Leist M, Moné M, Pastor M, van de Water B. Paradigm shift in safety assessment using new approach methods: The EU-ToxRisk strategy. Current Opinion in Toxicology 2019. [DOI: 10.1016/j.cotox.2019.03.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
12
|
Gómez-Tamayo J, Troger F, Pastor M, Norinder U, Zdrazil B, Ecker G. Ligand based and structural based modeling for the understanding, classification and prediction ofmitochondrial toxicity. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Pastor M, Westen G, Gómez-Tamayo J, Lenselink B, Lam CC, Water B, Norinder U, Manganelli S, Gadaleta D, Roncaglioni A. Development and validation of computational models for predicting oxidative stress responses using comprehensive series of drug-like compounds. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
14
|
Pastor M, Lopez Pousa A, del Barco E, Perez Segura P, Astorga BG, Castelo B, Bonfill T, Martinez Trufero J, Grau JJ, Mesia R. SEOM clinical guideline in nasopharynx cancer (2017). Clin Transl Oncol 2017; 20:84-88. [PMID: 29098554 PMCID: PMC5785612 DOI: 10.1007/s12094-017-1777-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Accepted: 10/17/2017] [Indexed: 11/26/2022]
Abstract
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiation therapy is an essential component of curative-intent of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.
Collapse
Affiliation(s)
- M. Pastor
- Servicio de Oncología Médica, Hospital La Fe de Valencia, Valencia, Spain
| | - A. Lopez Pousa
- Servicio de Oncología Médica - IIBSP, Hospital Sant Pau, Barcelona, Spain
| | - E. del Barco
- Servicio de Oncología Médica Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | - P. Perez Segura
- Servicio de Oncología Médica Hospital Clínico San Carlos, Madrid, Spain
| | - B. Gonzalez Astorga
- Servicio de Oncología Médica Hospital Universitario San Cecilio, Granada, Spain
| | - B. Castelo
- Servicio de Oncología Médica Hospital Universitario La Paz, Madrid, Spain
| | - T. Bonfill
- Servicio de Oncología Médica Corporació Sanitària Parc Taulí, Sabadell, Spain
| | - J. Martinez Trufero
- Servicio de Oncología Médica Hospital Universitario Miguel Servet, Saragossa, Spain
| | - J. Jose Grau
- Servicio de Oncología Médica, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
| | - R. Mesia
- Servicio de Oncología Médica, Institut Català d’Oncologia – Badalona, Barcelona, Spain
| |
Collapse
|
15
|
Bruixola G, Caballero J, Papaccio F, Petrillo A, Pastor M, Cervantes A. Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Rueda A, Giralt J, Mañós M, Lozano A, Sistiaga A, García-Miragall E, Cacicedo J, Esteban F, Scola B, Contreras J, Ruiz A, Carral A, Sanchez-Aniceto G, Pastor M, Herranz J, Bernal M, Mesía R. Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2). Oral Oncol 2017; 70:65-72. [DOI: 10.1016/j.oraloncology.2017.04.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Revised: 03/31/2017] [Accepted: 04/08/2017] [Indexed: 10/19/2022]
|
17
|
Moreno-Sastre M, Pastor M, Esquisabel A, Sans E, Viñas M, Bachiller D, Pedraz JL. Stability study of sodium colistimethate-loaded lipid nanoparticles. J Microencapsul 2016; 33:636-645. [PMID: 27682964 DOI: 10.1080/02652048.2016.1242665] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
In the last decades, the encapsulation of antibiotics into nanoparticulate carriers has gained increasing attention for the treatment of infectious diseases. Sodium colistimethate-loaded solid lipid nanoparticles (Colist-SLNs) and nanostructured lipid carriers (Colist-NLCs) were designed aiming to treat the pulmonary infection associated to cystic fibrosis patients. The nanoparticles were freeze-dried using trehalose as cryoprotectant. The stability of both nanoparticles was analysed over one year according to the International Conference of Harmonisation (ICH) guidelines by determining the minimum inhibitory concentration (MIC) against clinically isolated Pseudomonas aeruginosa strains and by studying their physico-chemical characteristics. The results showed that Colist-SLNs lost their antimicrobial activity at the third month; on the contrary, the antibacterial activity of Colist-NLCs was maintained throughout the study within an adequate range (MIC ≤16 μg/mL). In addition, Colist-NLCs exhibited suitable physico-chemical properties at 5 °C and 25 °C/60% relative humidity over one year. Altogether, Colist-NLCs proved to have better stability than Colist-SLNs.
Collapse
Affiliation(s)
- M Moreno-Sastre
- a NanoBioCel Group, Laboratory of Pharmaceutics , School of Pharmacy, University of the Basque Country (UPV/EHU) , Vitoria-Gasteiz , Spain.,b Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Vitoria-Gasteiz , Spain
| | - M Pastor
- a NanoBioCel Group, Laboratory of Pharmaceutics , School of Pharmacy, University of the Basque Country (UPV/EHU) , Vitoria-Gasteiz , Spain.,b Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Vitoria-Gasteiz , Spain
| | - A Esquisabel
- a NanoBioCel Group, Laboratory of Pharmaceutics , School of Pharmacy, University of the Basque Country (UPV/EHU) , Vitoria-Gasteiz , Spain.,b Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Vitoria-Gasteiz , Spain
| | - E Sans
- c Department of Pathology and Experimental Therapeutics , Medical School, University of Barcelona - IDIBELL , Barcelona , Spain
| | - M Viñas
- c Department of Pathology and Experimental Therapeutics , Medical School, University of Barcelona - IDIBELL , Barcelona , Spain.,d IINFACTS, CESPU , Gandra , Portugal
| | - D Bachiller
- e Development and Regeneration Programme , Fundación Investigaciones Sanitarias Islas Baleares (FISIB) , Bunyola (Balearic Islands) , Spain.,f Consejo Superior de Investigaciones Científicas (CSIC) , Bunyola (Balearic Islands) , 7110 , S pain
| | - J L Pedraz
- a NanoBioCel Group, Laboratory of Pharmaceutics , School of Pharmacy, University of the Basque Country (UPV/EHU) , Vitoria-Gasteiz , Spain.,b Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Vitoria-Gasteiz , Spain
| |
Collapse
|
18
|
Coloma CS, Amerigo J, Niño Ó, Daroqui JC, Akhoundova D, Escoin C, Sosa MM, Navarro E, Montalar J, Pastor M. Impact of second primary tumors of head and neck region after a previous tumor in that area. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw376.66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Sorino G, Gonzálvez A, Campillo N, Pastor M, Viñas M, Motas M, Cárceles MP. Association between urinary concentration of bisphenol A (BPA), type-2 diabetes and dietary habits in Spanish diabetic and non-diabetic patients. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Sans-Serramitjana E, Fusté E, Martínez-Garriga B, Merlos A, Pastor M, Pedraz J, Esquisabel A, Bachiller D, Vinuesa T, Viñas M. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. J Cyst Fibros 2016; 15:611-8. [DOI: 10.1016/j.jcf.2015.12.005] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Revised: 11/18/2015] [Accepted: 12/02/2015] [Indexed: 01/13/2023]
|
21
|
Escher S, Hoffmann-Dörr S, Pastor M, Partosch F, Schröder K, Mangelsdorf I. Update of time extrapolation factors for risk assessment: The benefit of combined databases and probabilistic analyses. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Sadd JL, Hall ES, Pastor M, Morello-Frosch RA, Lowe-Liang D, Hayes J, Swanson C. Ground-Truthing Validation to Assess the Effect of Facility Locational Error on Cumulative Impacts Screening Tools. Geography Journal 2015; 2015:1-8. [PMID: 0 DOI: 10.1155/2015/324683] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Researchers and government regulators have developed numerous tools to screen areas and populations for cumulative impacts and vulnerability to environmental hazards and risk. These tools all rely on secondary data maintained by government agencies as part of the regulatory and permitting process. Stakeholders interested in cumulative impacts screening results have consistently questioned the accuracy and completeness of some of these datasets. In this study, three cumulative impacts screening tools used in California were compared, and ground-truth validation was used to determine the effect database inaccuracy. Ground-truthing showed substantial locational inaccuracy and error in hazardous facility databases and statewide air toxics emission inventories of up to 10 kilometers. These errors resulted in significant differences in cumulative impact screening scores generated by one screening tool, the Environmental Justice Screening Method.
Collapse
Affiliation(s)
- J. L. Sadd
- Geology Department, Occidental College, 1600 Campus Road, Los Angeles, CA 90041, USA
| | - E. S. Hall
- US Environmental Protection Agency, Office of Research and Development, 109 T.W. Alexander Drive, Research Triangle Park, NC 27711-0001, USA
| | - M. Pastor
- Program for Regional and Environmental Equity, University of Southern California, 950 W. Jefferson Boulevard, JEF 102, Los Angeles, CA 90089-1291, USA
| | - R. A. Morello-Frosch
- Department of Environmental Science, Policy and Management & School of Public Health, University of California at Berkeley, 130 Mulford Hall, Berkeley, CA 94720-3114, USA
| | - D. Lowe-Liang
- US Environmental Protection Agency Region 9, 75 Hawthorne Street (ENF-4-1), San Francisco, CA 94105, USA
| | - J. Hayes
- US Environmental Protection Agency Region 9, 75 Hawthorne Street (ENF-4-1), San Francisco, CA 94105, USA
| | - C. Swanson
- US Environmental Protection Agency Region 9, 75 Hawthorne Street (ENF-4-1), San Francisco, CA 94105, USA
| |
Collapse
|
23
|
Moreno-Sastre M, Pastor M, Salomon CJ, Esquisabel A, Pedraz JL. Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. J Antimicrob Chemother 2015. [DOI: 10.1093/jac/dkv192] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
24
|
Quiviger M, Arfi A, Mansard D, Delacotte L, Pastor M, Scherman D, Marie C. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector. Gene Ther 2014; 21:1001-7. [DOI: 10.1038/gt.2014.75] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Revised: 05/17/2014] [Accepted: 07/15/2014] [Indexed: 12/23/2022]
|
25
|
Pastor M, Sabater S, Andrés I, Lozano E, Berenguer R, Sevillano M, Arenas M. EP-1419: Magnetic resonance imaging rigid and deformable pelvic registration accuracy related to the tabletop shape. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)31537-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Mesía R, Pastor M, Grau JJ, del Barco E. SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013. Clin Transl Oncol 2013; 15:1018-24. [PMID: 23982853 DOI: 10.1007/s12094-013-1096-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2013] [Accepted: 07/22/2013] [Indexed: 01/20/2023]
Abstract
Head and neck cancer represents 5 % of oncologic cases in adults. Early stage treatments are local with surgery and/or radiotherapy. For locally advanced stages, treatment requires radiotherapy combined with platinum-based drugs or cetuximab. Induction chemotherapy should be considered for selected cases. In the case of metastatic disease, adjuvant or palliative treatment is based on platinum agents and cetuximab.
Collapse
Affiliation(s)
- R Mesía
- Servicio de Oncología Médica, Institut Català d'Oncologia-L'Hopsitalet, Barcelona, Spain
| | | | | | | | | |
Collapse
|
27
|
Mesía R, Pastor M, Grau JJ, del Barco E. SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma 2013. Clin Transl Oncol 2013; 15:1025-9. [PMID: 23982852 DOI: 10.1007/s12094-013-1094-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 07/21/2013] [Indexed: 12/31/2022]
Abstract
Nasopharyngeal carcinoma cases are not frequently encountered in our environment. Local stages are treated with radiotherapy. For advanced local stages, the association of chemotherapy with radiotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum-based chemotherapy and patients may achieve a long survival time.
Collapse
Affiliation(s)
- R Mesía
- Servicio de Oncología Médica, Institut Català d'Oncologia-L'Hospitalet, Barcelona, Spain
| | | | | | | | | |
Collapse
|
28
|
Pastor M, Pedraz JL, Esquisabel A. The state-of-the-art of approved and under-development cholera vaccines. Vaccine 2013; 31:4069-78. [PMID: 23845813 DOI: 10.1016/j.vaccine.2013.06.096] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 06/20/2013] [Accepted: 06/26/2013] [Indexed: 11/19/2022]
Abstract
Cholera remains a huge public health problem. Although in 1894, the first cholera vaccination was reported, an ideal vaccine that meets all the requirements of the WHO has not yet been produced. Among the different approaches used for cholera vaccination, attenuated vaccines represent a major category; these vaccines are beneficial in being able to induce a strong protective response after a single administration. However, they have possible negative effects on immunocompromised patient populations. Both the licensed CVD103-HgR and other vaccine approaches under development are detailed in this article, such as the Vibrio cholerae 638 vaccine candidate, Peru-15 or CholeraGarde(®) and the VA1.3, VA1.4, IEM 108 VCUSM2 and CVD 112 vaccine candidates. In another strategy, killed V. cholerae vaccines have been developed, including Dukoral(®), mORCAX(®) and Sanchol™. The killed vaccines are already sold, and they have successfully demonstrated their potential to protect populations in endemic areas or after natural disasters. However, these vaccines do not fulfill all the requirements of the WHO because they fail to confer long-term protection, are not suitable for children under two years, require more than a single dose and require a distribution chain with cold storage. Lastly, other vaccine strategies under development are summarized in this review. Among these strategies, vaccine candidates based on alternative drug delivery systems that have been reported lately in the literature are discussed, such as microparticles, proteoliposomes, LPS subunits, DNA vaccines and rice seeds containing toxin subunits. Preliminary results reported by many groups working on alternative delivery systems for cholera vaccines demonstrate the importance of new technologies in addressing old problems such as cholera. Although a fully ideal vaccine has not yet been designed, promising steps have been reported in the literature resulting in hope for the fight against cholera.
Collapse
Affiliation(s)
- M Pastor
- NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain
| | | | | |
Collapse
|
29
|
Cases M, Pastor M, Sanz F. The eTOX Library of Public Resources for in Silico Toxicity Prediction. Mol Inform 2013; 32:24-35. [DOI: 10.1002/minf.201200099] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Accepted: 11/20/2012] [Indexed: 12/29/2022]
|
30
|
Sadiq SK, Guixa-Gonzalez R, Dainese E, Pastor M, De Fabritiis G, Selent J. Molecular modeling and simulation of membrane lipid-mediated effects on GPCRs. Curr Med Chem 2013; 20:22-38. [PMID: 23151000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Revised: 09/21/2012] [Accepted: 09/24/2012] [Indexed: 06/01/2023]
Abstract
Functioning of G protein-coupled receptors (GPCRs) is tightly linked to the membrane environment, but a molecular level understanding of the modulation of GPCR by membrane lipids is not available. However, specific receptor-lipid interactions as well as unspecific effects mediated by the bulk properties of the membrane (thickness, curvature, etc.) have been proposed to be key regulators of GPCR modulation. In this review, we examine computational efforts made towards modeling and simulation of (i) the complex behavior of membrane lipids, (ii) membrane lipid-GPCR interactions as well as membrane lipid-mediated effects on GPCRs and (iii) GPCR oligomerization in a native-like membrane environment. We propose that, from the perspective of computational modeling, all three of these components need to be addressed in order to achieve a deeper understanding of GPCR functioning. Presently, we are able to simulate numerous lipid properties applying advanced computational techniques, although some barriers, such as the time-length of these simulations, need to be overcome. Implementing three-dimensional structures of GPCRs in such validated membrane systems can give novel insights in membrane-dependent receptor modulation and formation of higher order receptor complexes. Finally, more realistic GPCR-membrane models would provide a very useful tool in studying receptor behavior and its modulation by small drug-like ligands, a relevant issue for drug discovery.
Collapse
Affiliation(s)
- S K Sadiq
- Computational Biophysics Lab, Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Dr. Aiguader, 88. Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
31
|
Sadiq S, Guixa-Gonzalez R, Dainese E, Pastor M, De Fabritiis G, Selent J. Molecular Modeling and Simulation of Membrane Lipid-Mediated Effects on GPCRs. Curr Med Chem 2012. [DOI: 10.2174/0929867311320010004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
32
|
Gursu M, Aydin Z, Karadag S, Uzun S, Ogul S, Kiris A, Doventas Y, Koldas M, Ozturk S, Kazancioglu R, Mandreoli M, Bellasi A, Baldrati L, Corradini M, Rigotti A, Russo G, David S, Malmusi G, DiNicolo' P, Orsi C, Zambianchi L, Caruso F, Poisetti P, Fabbri A, Santoro A, Barton Pai A, Grabe D, Eisele G, Hutchison CA, Bevins A, Lukacik P, Hughes RG, Pratt G, Viana JL, Bishop NC, Kosmadakis G, Bevington A, Clapp EL, Feehally J, Smith AC, Joki N, Hase H, Tanaka Y, Iwasaki M, Yamaka T, Shigematsu T, Dou L, Gondouin B, Cerini C, Duval-Sabatier A, Poitevin S, Dignat-George F, Burtey S, Brunet P, Carrasco F, Salvador F, Origaca C, Nogueira E, Silva N, Silva A, Sikole A, Trajceska L, Selim G, Gelev S, Dzekova P, Amitov V, Arsov S, Dalboni M, Cruz E, Manfredi S, Mouro M, Quinto M, Grabulosa C, Batista M, Cendoroglo M, Hirayama A, Matsui H, Nagano Y, Ueda A, Aoyagi K, Owada S, Schepers E, Barreto D, Liabeuf S, Glorieux G, Eloot S, Barreto F, Massy Z, Vanholder R, Secara IF, Oleniuc M, Nistor I, Onofriescu M, Covic A, Aguerrevere S, Granada M, Bayes B, Pastor M, Sancho A, Bonal J, Canas L, Lauzurica R, Teixido J, Troya M, Romero R, Capitanini A, D'Alessandro C, Ferretti V, Petrone I, Pasquariello G, Cupisti A, Parastayeva MM, Berseneva ON, Kucher AG, Ivanova GT, Smirnov AV, Kayukov IG, Kayabasi H, Esmer S, Yilmaz Z, Kadiroglu AK, Yilmaz ME, Radic J, Kovacic V, Radic M, Ljutic D, Sain M, Karakan S, Sezer S, Tutal E, Ozdemir Acar FN, Bi G, Xing C, Chen R, Romero-Garcia A, Jacobo-Arias F, Martin del Campo F, Gonzalez-Espinoza L, Pazarin L, Cueto-Manzano AM, Panagoutsos S, Kriki P, Mourvati E, Tziakas D, Chalikias G, Stakos D, Apostolakis S, Tsigalou C, Gioka T, Konstantinides S, Vargemezis V, Nascimento M, Hayashi S, Seeberger A, Yamamoto T, Qureshi AR, Lind B, Riella M, Brodin LA, Lindholm B, Meier P, Menne J, Kruger K, Mooren FC, Weissmann N, Seimetz M, Haller H, Gusev E, Solomatina L, Zhuravleva J, Striker G, Uribarri J, Cai W, Goodman S, Pyzik R, Grosjean F, Vlassara H, So A, Gimona A, Kiechle T, Shpilsky A, Schlesinger N. Malnutrition & inflammation in CKD 1-5. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Obiol-Pardo C, Gomis-Tena J, Saiz J, Pastor M, Sanz F. A cardiotoxicity prediction system based on multiscale modeling. Toxicol Lett 2010. [DOI: 10.1016/j.toxlet.2010.03.850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
34
|
Steger-Hartmann T, Pognan F, Sanz F, Diaz C, Sutter A, Pastor M. In silico prediction of in vivo toxicity - the first steps of the e-Tox consortium. Toxicol Lett 2010. [DOI: 10.1016/j.toxlet.2010.03.838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML, Fournel-Fleury C. A Morphological Study of 608 Cases of Canine Malignant Lymphoma in France With a Focus on Comparative Similarities Between Canine and Human Lymphoma Morphology. Vet Pathol 2010; 47:414-33. [DOI: 10.1177/0300985810363902] [Citation(s) in RCA: 152] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
This study reports cytomorphological, histomorphological, and immunological characterization of 608 biopsy cases of canine malignant lymphoma, with epidemiological and clinical data, collected from 7 French veterinary pathology laboratories. It compares morphological characteristics of malignant lymphoma in canines, per the updated Kiel classification system, with those reported in humans, per the World Health Organization (WHO) classification system. Of tumors described, 24.5% and 75.5% were classified as low- and high-grade malignant lymphomas, respectively. Presenting clinical signs included generalized or localized lymphadenopathy (82.4%) and extranodal diseases (17.6%) involving the skin (12.34%) and other sites (5.26%). Immunohistochemistry confirmed 63.8% B-cell (CD3–, CD79a+), 35.4% T-cell (CD3+, CD79a–), and 0.8% null-cell (CD3–, CD79a–) lymphomas. Most B-cell cases (38.49%) were of high-grade centroblastic polymorphic subtype; most T-cell cases (8.55%), high-grade pleomorphic mixed and large T-cell lymphoma subtypes. Some B-cell tumors showed morphologic characteristics consistent with follicular lymphomas and marginal zone lymphomas per the Revised European American Classification of Lymphoid Neoplasms and WHO canine classification systems and the WHO human classification system. Unusual high-grade B-cell subtypes included an atypical high-grade small B-cell lymphoma (0.66%), Burkitt-type B-cell lymphoma (1.64%), plasmacytoid lymphoma (0.99%), and mediastinal anaplastic large B-cell lymphoma (0.16%). Unusual T-cell subtypes included a previously undescribed high-grade canine immunoblastic T-cell type (1.15%), a rare low-grade prolymphocytic T-cell lymphoma (0.16%), and a recently described high-grade canine T-cell entity—aggressive granulocytic large-cell lymphoma (0.16%). Marginal zone lymphomas were common (10.86%); follicular lymphomas were rare (0.49%). Canine primary cutaneous malignant lymphoma subtypes were present (11.84%). There was no significant difference between B- and T-cell malignant lymphoma in regard to canine age and sex. A significant overrepresentation of Boxers (24.19%) was found for T-cell lymphomas.
Collapse
Affiliation(s)
- F. Ponce
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| | - T. Marchal
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| | - J. P. Magnol
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| | - V. Turinelli
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| | - D. Ledieu
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| | - C. Bonnefont
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| | - M. Pastor
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| | - M. L. Delignette
- Unité de Biomathématiques, Ecole Nationale Vétérinaire de Lyon, France
| | - C. Fournel-Fleury
- Laboratoire de Pathologie Clinique et Unité d’Oncologie, Ecole Nationale Vétérinaire de Lyon, France
| |
Collapse
|
36
|
Salas J, Pastor M, Castro J. Influencia del riego sobre la composición y características organolépticas del aceite de oliva. Grasas y Aceites 2010. [DOI: 10.3989/gya.1997.v48.i2.771] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
37
|
López-Tarruella S, López-Tarruella S, Puente J, Lluch A, Climent M, Pastor M, Alba E, Mayordomo J, Díaz-Rubio E, Casado A, Casado A, Cano S, Martín M, Martín M. Impact on Survival of Primary Tumor Resection in Women with Metastatic Breast Cancer at Initial Diagnosis. The Alamo Project. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent medical and scientific reports suggest that surgery of the primary tumor (PT) could be taken into account, although far from the current standard of care, in metastatic breast cancer (MBC) patients. The mechanistic basis for these findings stem from crosstalk between the PT and metastatic foci, immunosuppressive effects, and/or the avoidance of metastatic re-seeding from the primary source. We have focused on implementing surgical excision of the PT in certain settings and tumor types in order to ascertain whether this aggressive treatment modality can be justified in a classic palliative setting. Methods: The ALAMO Project (A) is a retrospective analysis of patients (pts) diagnosed with BC between 1990 and 1997 across 43 GEICAM hospitals. Patterns of BC presentation (tumor and host characteristics), treatment and survival were recorded in 2 cohorts, AI (1990-93, 4532 pts, closed by 2000) and AII (1994-97, 10849 pts, closed by 2003). Only MBC pts at first diagnosis were included, excluding those with secondary tumors, without a minimum of 2 months follow-up at the same institution, and without complete information regarding their PT surgery. Descriptive, Kaplan-Meier and Cox regression analyses were carried out. Results: 6.12% of the ALAMO database pts were initially diagnosed with MBC (605 fulfilled the present analysis criteria), with a medium age of 61.6 years (yrs). 54.2% had single-organ metastasis, anatomically distributed in skin/soft tissue (18.8%), bone (35.9%), lung (9.8%), and other viscera (35.5%). 26.3% of pts had surgery of the PT (83.7% of them radical procedures, 73.3% of them axillary dissected and 5.6% received radiotherapy). Chemotherapy (30.7%), endocrine therapy (23.1%) or both (41.7%) were the systemic approaches, and 4.5% received supportive care. Women in the surgery (S) group (159 pts) were younger, with skin/soft tissue or bone metastasis and oligometastatic disease. 5-yr overall survival (OS) was 18.84%, 2.94 yrs median OS in the S-group versus 1.83 yrs in the nS-group (p<0.001). A stratified analysis by organ showed relevant effects of surgery for pts with skin/soft tissue metastasis, 4.52 yrs versus 1.77 yrs median OS in the S and nS arms respectively. The multi-adjusted HR for surgery in this subgroup was 0.30 (p<0.001), which was not significantly modified considering a propensity score (PS) factor (HR 0.29, p<0.001). Surgery (p<0.001), systemic treatment (p<0.001), and the interaction between surgery and metastatic location (p<0.004) were included in the multivariate predictive model of survival for the whole series. Discussion: Local surgery of the PT is associated with an increase in OS for pts with skin/soft tissue metastasis and is maintained in multi-adjusted models. These analyses suggest that loco-regional control of the PT should be considered for the treatment of advanced disease in selected patients, but must be further investigated in randomized controlled trials in MBC at first diagnosis.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3104.
Collapse
Affiliation(s)
| | | | - J. Puente
- 2Hospital Clínico San Carlos, Madrid, Spain
| | - A. Lluch
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - M. Climent
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - M. Pastor
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - E. Alba
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - J. Mayordomo
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | | | - A. Casado
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - A. Casado
- 2Hospital Clínico San Carlos, Madrid, Spain
| | - S. Cano
- 2Hospital Clínico San Carlos, Madrid, Spain
| | - M. Martín
- 1Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain
| | - M. Martín
- 2Hospital Clínico San Carlos, Madrid, Spain
| |
Collapse
|
38
|
Pastor M, Chalvet-Monfray K, Marchal T, Keck G, Magnol JP, Fournel-Fleury C, Ponce F. Genetic and environmental risk indicators in canine non-Hodgkin's lymphomas: breed associations and geographic distribution of 608 cases diagnosed throughout France over 1 year. J Vet Intern Med 2009; 23:301-10. [PMID: 19192140 DOI: 10.1111/j.1939-1676.2008.0255.x] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND The etiology of non-Hodgkin's lymphomas (NHL) is multifactorial. Environmental and genetic factors are frequently incriminated both in humans and dogs. OBJECTIVES Our purpose was to study the geographic distribution of canine NHL (CNHL) in France and to evaluate genetic and environmental influences. ANIMALS Six hundred and eight cases of CNHL, diagnosed throughout France over 1 year, were collected from 7 Veterinary Histopathologic Laboratories. METHODS Retrospective study. Breeds affected by lymphomas were compared with the national population and associations between breed and immunophenotype were studied. The distribution of CNHL and canine T-cell NHL per 100,000 dogs per department was compared with the distribution of waste incinerators, polluted sites, and radioactive waste. RESULTS The breeds significantly overrepresented among lymphoma cases were Boxer, Setter, and Cocker Spaniel (P < .001). There was a significant association between Boxer and T-cell NHL (P < .001), and between German Shepherd and Rottweiler and B-cell NHL (P < .01). The geographic distribution of CNHL and canine T-cell NHL indicated significant heterogeneity. Significant association between distributions of CNHL and waste incinerators (rho= 0.25, P < .05), polluted sites (rho= 0.36, P < .001), and radioactive waste (rho= 0.51, P < .001) was found. CONCLUSIONS AND CLINICAL IMPORTANCE Influence of genetics in the development of CNHL was supported by the existence of an association between breed and immunophenotype. Waste incinerators, polluted sites, and radioactive waste could just be considered as risk indicators of CNHL, but not as risk factors. Case-control studies around critical sites are necessary to confirm the implication of those environmental factors in the development of CNHL.
Collapse
Affiliation(s)
- M Pastor
- Unité de Médecine Interne, Ecole Nationale Vétérinaire de Lyon, Université de Lyon, 69280 Marcy l'Etoile, France.
| | | | | | | | | | | | | |
Collapse
|
39
|
Lluch A, Ruiz A, Martín M, Alba E, Pastor M, de la Haba J, Llombart A, Ramos M, Martínez del Prado P, Escudero M. Combination or sequential single agent for the treatment of metastatic breast cancer (MBC) patients (pts). Impact of further chemotherapy (CT) in overall survival (OS) in the Alamo registry. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2121
Introduction: Combinations can improve OS in MBC; however sequential single agent is sometimes preferred. In a recent report, pts receiving paclitaxel monotherapy in first line had a significantly worse OS if they were not receiving post study CT (PSC); no difference was seen in pts receiving paclitaxel+gemcitabine (Llombart, EBCC 2008). In this trial only 58% of pts received PSC.
 Purpose: To assess, outside the context of a clinical trial, the amount of MBC pts receiving CT beyond first line, as well as the impact of combination use and further CT lines in their OS.
 Methods: Alamo 1-2 is a breast cancer patient registry run by the GEICAM. 15482 pts diagnosed from 1990-1997 in 54 sites were included in the database. 4668 pts were stage IV; 778 (16.7%) metastatic at diagnosis and 3890 (83.3%) have had a recurrence.
 Results: 3045 (65%) pts received CT in first line, 83% were combinations (with anthracyclines 42%, CMF 16%, taxane+anthracyclines 9.4% or +other agents 8%) and 16% were monotherapy. Among other variables studied, only previous treatment (in early stage) was influencing the choice of a combination (pts without previous CT received more combinations than pts receiving CMF, than pts receiving anthracyclines). Median survival for pts receiving single agent was significantly shorter compared to pts receiving combination, 16.2 and 21.85 months (m) respectively, HR=1.37 (IC 95%: 1.21-1.55; p<0.0001). Several covariates showed significant prognostic value in survival in the Cox multivariate model: monotherapy treatment in first line, anthracyclines pre-exposure, age > 65, negative hormonal receptor status, hepatic disease, Grade 3 and ≥ 3 disease sites. Half of the pts never received further CT after first line treatment. Only age and number of disease sites were influencing this decision in the Cox multivariate model. Median survival was 24.9 m in pts receiving further CT and 14.5 m in the ones not receiving it. In pts not receiving further CT, median OS was significantly shorter if they were treated with single agent in first line in comparison to those receiving previous combination: HR= 1.59 (IC 95%: 1.33-1.89; p< 0,00001). This difference was not significant in pts receiving further CT: HR= 1.15 (IC 95%: 0.97-1.37; p=0.101).
 Conclusion: Our data show that only half of the MBC pts receive further CT after first line; they have longer survival. We found significant evidence that further CT is impacting the OS in pts treated with single agent in first line, but not in those receiving previous combination. Those facts should be taken into consideration when selecting single agent or a combination in first line.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2121.
Collapse
Affiliation(s)
- A Lluch
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - A Ruiz
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - M Martín
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - E Alba
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - M Pastor
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - J de la Haba
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - A Llombart
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - M Ramos
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - P Martínez del Prado
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| | - M Escudero
- 1 H C U Valencia, Valencia, Spain
- 2 IVO, Valencia, Spain
- 3 H C U San Carlos, Madrid, Spain
- 4 C H Virgen de la Victoria, Málaga, Spain
- 5 H U La Fe, Valencia, Spain
- 6 C H Reina Sofía, Córdoba, Spain
- 7 H U Arnau de Vilanova, Lleida, Spain
- 8 C O Galicia, A Coruña, Spain
- 9 H Basurto, Bilbao, Spain
- 10 GEICAM, Madrid, Spain
| |
Collapse
|
40
|
Oltra A, Santaballa A, Munárriz B, Pastor M, Montalar J. Cost-Benefit Analysis of a Follow-up Program in Patients with Breast Cancer: A Randomized Prospective Study. Breast J 2007; 13:571-4. [DOI: 10.1111/j.1524-4741.2007.00506.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
41
|
Hitt R, Irigoyen A, Nuñez J, Grau J, Garcia Saenz J, Pastor M, Jara C, Garcia Giron C, Hidalgo M, Cruz Hernandez J. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6012] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6012 Background: Cetuximab and paclitaxel have shown to be active in SCCHN pts and preclinical data has demonstrated a possible synergy for the combination. In a variety of tumor types, weekly paclitaxel has demonstrated an improved safety profile and activity as compared to every 3 weeks paclitaxel, providing the rationale to study the combination of cetuximab and weekly paclitaxel in metastatic/recurrent SCCHN. Methods: Pts were required to have a y performance status (KPS) = 70%, measurable disease using RECIST criteria, and may have received one regimen of induction and/or concomitant chemotherapy, but not within the recurrent/metastatic setting. Treatment included weekly paclitaxel 80 mg/m2 and cetuximab (initial dose of 400 mg/m2, followed by a weekly infusion of 250 mg/m2). Biopsies of tumors and samples of blood are being analyzed for correlative markers including EGFR gene copy number -FISH-, polymorphisms of intron 1 of the EGFR, and downstream EGFR pathway markers and mutations. Results: 46 planned pts were enrolled from Ap-2006 to Sep-2006. Median age is 60 years (range 42–78). Median KPS is 80% (range 70–100%). 35 pts are evaluable for response. Complete responses have been observed in 7 pts, partial responses in 18 pts, and stable disease in 6 pts for an overall response rate of 71% and disease control rate of 88%. 44 pts are evaluable for safety. Main grade 3/4 toxicities(NCI): 8 pts had acne- like rash; 7 neutropenia but only 1 febrile neutropenia; 6 asthenia; 3 mucositis; 2 infusion related reactions to paclitaxel and 1 to cetuximab; 2 peripheral neuropathies; 1 diarrhea; 1 vomiting; and 1 conjunctivitis. Conclusions: This trial shows that the combination of cetuximab and weekly paclitaxel is well tolerated and provides very encouraging activity in advanced/recurrent SCCHN. The full data, including biomarker results, will be presented at the annual meeting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Hitt
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - A. Irigoyen
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - J. Nuñez
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - J. Grau
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - J. Garcia Saenz
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - M. Pastor
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - C. Jara
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - C. Garcia Giron
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - M. Hidalgo
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| | - J. Cruz Hernandez
- Hospital 12 de Octubre, Madrid, Spain; Hospital Granada, Granada, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clinico, Madrid, Spain; Hospital Valencia, Valencia, Spain; Hospital Alcorcon, Madrid, Spain; Hospital Burgos, Burgos, Spain; John Hopkins University, Baltimore, MD; Hospital Clinico Salamanca, Salamanca, Spain
| |
Collapse
|
42
|
|
43
|
Oltra A, Aparicio J, Pastor M, Maestu I. [Gastrointestinal bleeding as presentation of a testicular germ cell tumor]. Rev Esp Enferm Dig 2006; 98:477-8. [PMID: 16948547 DOI: 10.4321/s1130-01082006000600010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
44
|
Martín M, Mahillo E, Llombart-Cussac A, Lluch A, Munarriz B, Pastor M, Alba E, Ruiz A, Antón A, Bermejo B. The «El Álamo» project (1990–1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Clin Transl Oncol 2006; 8:508-18. [PMID: 16870541 DOI: 10.1007/s12094-006-0051-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND The "Alamo" project is a retrospective analysis of 14,854 patients diagnosed of breast cancer between 1990 and 1997 in 50 Spanish hospitals. METHODS Alamo I (AI) consisted of 4,532 patients diagnosed with breast cancer between 1990 and 1993. Data were collected in 2000. Alamo II (AII) consisted of 10,322 patients diagnosed between 1994 and 1997. Data were collected in 2003. RESULTS At presentation, there were (AI vs. AII) 17.6% vs. 24.3% at stage I; 55.5% vs. 53.1% at stage II; 18.7% vs. 15% at stage III; 7.2% vs. 5.9 at stage IV. Median age was 57 (AI) vs. 58 years (AII) and 65.9% vs. 67.2% (AI vs. AII) were post-menopausal. Firstline treatment for disease stages I, II and III was surgery in 91% of patients in both studies. Breast conserving surgery rate increased from 20.2% (AI) to 32.7% (AII). Adjuvant systemic treatments were administered to 87.6% (AI) and 92.8% (AII) of patients. Recurrence rate diminished from 36.6% (AI) to 22.5% (AII) and the 9-year survival rate increased from 63.2% (95% CI: 61.5-64.9) to 70.1% (95% CI: 68.5-71.8). CONCLUSION Breast cancer outcomes in Spain have improved from 1990-1993 to 1994-1997, likely because of breast cancer screening program implementation and new therapies.
Collapse
Affiliation(s)
- M Martín
- Hospital Clínico Universitario San Carlos, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
|
46
|
Casado A, Ruiz A, Lluch A, Pastor M, Antón A, Martínez Del Prado P, Fernández-Aramburo A, Alba E, Aranda E, Mahillo E. Spanish Breast Cancer Research Group (GEICAM) population-based study on breast cancer outcomes (El Álamo project): Analysis of operable, node negative breast cancer patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Casado
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - A. Ruiz
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - A. Lluch
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - M. Pastor
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - A. Antón
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - P. Martínez Del Prado
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - A. Fernández-Aramburo
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - E. Alba
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - E. Aranda
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| | - E. Mahillo
- Hosp Clínico U San Carlos, Madrid, Spain; Inst Valenciano de Oncología, Valencia, Spain; Hosp Clínico U. de Valencia, Valencia, Spain; Hosp U. La Fe, Valencia, Spain; Hosp U. Miguel Servet, Zaragoza, Spain; Hosp de Basurto, Bilbao, Spain; Hosp Gral. de Albacete, Albacete, Spain; Hosp U. Virgen de la Victoria, Málaga, Spain; Complejo Hospitalario Reina Sofia, Córdoba, Spain; GEICAM, Madrid, Spain
| |
Collapse
|
47
|
Berrocal A, Pastor M, Caballero C, Segura A, Garcera S, Oltra A, Nogueron E, Blasco A, Lopez P, Camps C. Phase II study of paclitaxel, tegafur/uracil and folinic acid as first line treatment in metastatic or recurrent head and neck squamous cell carcinomas. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Berrocal
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - M. Pastor
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - C. Caballero
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - A. Segura
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - S. Garcera
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - A. Oltra
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - E. Nogueron
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - A. Blasco
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - P. Lopez
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| | - C. Camps
- Hospital General Universitario, Valencia, Spain; Hospital La Fe, Valencia, Spain; Hospital de la Ribera, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital de Albacete, Albacete, Spain
| |
Collapse
|
48
|
González-Navarro H, Mora P, Pastor M, Serrano L, Mingarro I, Pérez-Payá E. Identification of peptides that neutralize bacterial endotoxins using beta-hairpin conformationally restricted libraries. Mol Divers 2002; 5:117-26. [PMID: 12197068 DOI: 10.1023/a:1016207717213] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Bacterial endotoxins are the major mediator of septic shock; therefore, endotoxin-neutralizing molecules could have biomedical applications. The septic shock cascade relies in a series of molecular recognition processes. The large contact-surface described for the interacting macromolecules, in most cases, prevents the identification of small molecules that could modulate such recognition events. Here we report on a beta-hairpin conformationally restricted combinatorial library that has been generated and screened towards the identification of new peptides that neutralize bacterial endotoxins. Starting with a de novo designed linear peptide that shows a beta-hairpin structure population of around 30%, (Ramirez-Alvarado, M., Blanco, F. J. and Serrano, L. Nat. Struc. Biol., 7, 604-612 (1996)), we selected four positions to build up a combinatorial library of 20(4) sequences. Deconvolution of the library reduced such a sequence complexity to 8 defined sequences. The newly identified peptides have a biological activity equivalent to that reported for peptides derived from natural endotoxin-binding proteins.
Collapse
Affiliation(s)
- H González-Navarro
- Dept. Bioquímica i Biologia Molecular, Universitat de València, E-46100 Burjassot, València, Spain
| | | | | | | | | | | |
Collapse
|
49
|
Herranz R, Husson D, Pastor M, Diaz C, Mateos J, Villa A, Medina FJ, Marco R. Towards the establishment of a permanent colony of Drosophila in the International Space Station: hardware tests and adaptation of techniques. J Gravit Physiol 2002; 9:P357-8. [PMID: 15002613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Our group has the long-term goal of establishing a permanent colony of Drosophila melanogaster in the International Space Station (ISS) to study its long-term adaptation to this unusual environment. We are currently building an enhanced version of an automatic cultivation unit (ESE1) in which we can grow flies with minimal crew involvement. We are working on a fixation unit as well. We are also adapting current protocols to maintain fixed animals during at least three months, the minimal refurbishment shuttle flight time, with minimal handling and maximal automatization, that can be used for inmuno-cytochemistry, ultrastructure or molecular experiments.
Collapse
|
50
|
Martínez F, Nos P, Pastor M, Garrigues V, Ponce J. Adverse effects of azathioprine in the treatment of inflammatory bowel disease. Rev Esp Enferm Dig 2001; 93:769-78. [PMID: 11995359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
OBJECTIVE To know the type, frequency and time course for the occurrence of adverse events in our series of patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. PATIENTS AND METHOD 92 consecutive patients were treated with azathioprine. 70 of them (55 Crohn's disease, 14 ulcerative colitis and 1 undetermined colitis) were suitable for analysis. RESULTS We observed 23 adverse reactions in 21 patients. Adverse events were as follows: haematological 11.4%, digestive intolerance 11.4%, infection 7.1%, and pancreatitis 2.8%. The prevalence was increased among ulcerative colitis patients (57.8 vs. 21.8%) (p = 0.02). There were no statistical differences in the prevalence of adverse events respective of the age, gender or location of disease. Digestive intolerance and pancreatitis occurred within the first 6 months of therapy, whereas haematological side effects occurred between 3 months and 4 years after therapy onset. Early occurrence (but not late occurrence) was associated with thiopurine methyltransferase (TMPT) activity levels. All infections took place between 8 months and 5 years of treatment. Azathioprine was definitively withdrawn due to side effects in 9 cases (12.8%). CONCLUSIONS The frequency of adverse events in our study is similar to that reported in previous studies. Azathioprine withdrawal is required in almost half of the cases because of toxicity. Frequency of side effects is increased in patients with ulcerative colitis. The variability in time course makes clinical-biological monitoring mandatory.
Collapse
Affiliation(s)
- F Martínez
- Servicio de Medicina Digestiva, Hospital La Fe, Valencia, Spain.
| | | | | | | | | |
Collapse
|